| |
Prospective Randomized Clinical Trial of the Effects of Three Modern Antiretroviral Therapies on Carotid Intima-Media Thickness in HIV-Infected Individuals (ACTG A5260s)
|
| |
| |
Reported by Jules Levin
James H. Stein1, Howard N. Hodis2, Todd T. Brown3, Heather Ribaudo4, Thuy Tien T. Tran4, Mingzhu Yan2, Elizabeth Lauer-Brodell1, Grace A. McComsey5, Michael P. Dube2, Robert L. Murphy6, Judith S. Currier7
1University of Wisconsin School of Medicine and Public Health, 2Keck School of Medicine at the University of Southern California, 3Johns Hopkins University, 4Harvard School of Public Health,
5Case School of Medicine, 6Feinberg School of Medicine at Northwestern University, 7David Geffen School of Medicine at University of California - Los Angeles
Bilirubin is a potent antioxidant, so the low level elevation of bilirubin that is seen with atazanavir may be a good thing. This is one of the possible major hypotheses about why the ATV group progressed more slowly in A5260s.
|
|
| |
| |
|
|
|
